Browse
Explore clinical trials and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
89497 trials found · Page 116 of 4475
-
Brain tumor trial tailors therapy to Kids' genetic profiles
Disease control OngoingThe study PNET 5 MB has been designed for children with medulloblastoma of standard risk (according to the risk-group definitions which have been used so far; e.g. in PNET 4). With the advent of biological parameters for stratification into clinical medulloblastoma trials, the ß-…
Phase: PHASE2, PHASE3 • Sponsor: Universitätsklinikum Hamburg-Eppendorf • Aim: Disease control
Last updated Apr 26, 2026 19:35 UTC
-
Could brain zaps slow Parkinson's? new trial aims to find out
Disease control Not yet recruitingThe goal of this trial is to evaluate the preliminary safety and efficacy of programming to maximize stimulation of the dorsolateral region of the subthalamic nucleus (STN) receiving primary motor (M1) and supplementary motor area (SMA), but not pre-SMA, input deep brain stimulat…
Phase: NA • Sponsor: Mallory Hacker • Aim: Disease control
Last updated May 03, 2026 08:09 UTC
-
AI tailors emergency treatment for deadly aortic tear
Disease control Not yet recruitingAortic dissection has acute onset and high mortality, with immunoinflammatory response driving lesion progression. Current perioperative anti-inflammatory therapies are mostly empirical and poorly targeted, and AI-assisted typing lacks a complete clinical translation pathway. Thi…
Phase: NA • Sponsor: Nanjing Medical University • Aim: Disease control
Last updated Apr 30, 2026 15:52 UTC
-
New pill combo aims to tame tough leukemia
Disease control Not yet recruitingThe goal of Part 1 of this clinical research study is to find the highest tolerable dose of cladribine that can be given in combination with low dose cytarabine (LDAC) and venetoclax to patients who have AML. The goal of Part 2 of this clinical research study is to learn if the …
Phase: PHASE1, PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Apr 30, 2026 15:50 UTC
-
New heart device aims to cut stroke risk without lifelong pills
Disease control Not yet recruitingThe Conscious Sedation Single Arm Sub-Study is designed to evaluate the safety and performance of the CLAAS device implantation procedure using conscious sedation.
Phase: NA • Sponsor: Conformal Medical, Inc • Aim: Disease control
Last updated Apr 29, 2026 15:01 UTC
-
Can a simple shot cut COPD attacks by 20%? new trial aims to find out.
Disease control Not yet recruitingObjectives: To determine whether respiratory syncytial virus (RSV) vaccination reduces the rate of all-cause moderate-to-severe acute exacerbations of COPD (AECOPD) in high-risk patients, and to characterise RSV-specific infection and immune responses in this population. Hypothe…
Phase: PHASE4 • Sponsor: Chinese University of Hong Kong • Aim: Disease control
Last updated Apr 29, 2026 15:04 UTC
-
Old cancer drug shows new promise for rare, painful skin diseases
Disease control Not yet recruitingEpidermal growth factor receptor (EGFR) signaling plays a key role in regulating epidermal cell proliferation, survival, and differentiation. Keratins form a scaffold with epidermal desmosomes that involves ErbB/ EGFR signaling and keratin deficiency makes keratinocytes more sens…
Phase: PHASE1, PHASE2 • Sponsor: Northwestern University • Aim: Disease control
Last updated Apr 30, 2026 15:52 UTC
-
New drug combo aims to shrink lung tumors before surgery in targeted trial
Disease control Not yet recruitingThis phase II trial tests how well zipalertinib with carboplatin and pemetrexed works in treating stage II-IIIB non small cell lung cancer. that can be removed by surgery (resectable). Zipalertinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell…
Phase: PHASE2 • Sponsor: Jonsson Comprehensive Cancer Center • Aim: Disease control
Last updated May 03, 2026 08:04 UTC
-
New immune combo aims to slow bile duct cancer
Disease control Not yet recruitingThis is a Randomized, Open-Label, Multicenter Phase 2 Study to access the efficacy and safety of Envafolimab in Combination with Gemcitabine Plus Cisplatin Versus Gemcitabine Plus Cisplatin as the First-line Treatment in Patients with Locally Advanced or Metastatic Biliary Tract …
Phase: PHASE2 • Sponsor: 3D Medicines (Sichuan) Co., Ltd. • Aim: Disease control
Last updated Apr 24, 2026 16:20 UTC
-
Emergency anthrax drug to be tested in mass exposure scenario
Disease control Not yet recruitingThis study will evaluate safety and clinical benefit of AIGIV used for treatment of patients with inhalational anthrax. This study will be implemented only in the event of a major anthrax exposure event. The study is designed to collect information on safety, clinical benefit (su…
Sponsor: Emergent BioSolutions • Aim: Disease control
Last updated May 01, 2026 15:57 UTC
-
New study aims to prevent Life-Threatening clots in hospitalized teens
Prevention Not yet recruitingCritically ill adolescents are at greatest risk for developing hospital-acquired venous thromboembolism. To date, no phase 3 randomized controlled trials have been conducted for pharmacological thromboprophylaxis as primary venous thromboembolism prevention in children. The inves…
Phase: PHASE3 • Sponsor: Johns Hopkins All Children's Hospital • Aim: Prevention
Last updated May 03, 2026 08:06 UTC
-
Can a phone app stop suicidal thoughts? new study aims to find out.
Symptom relief Not yet recruitingThis study aims to evaluate the acceptability, safety, and efficacy of a smartphone-delivered intervention called Therapeutic Evaluative Conditioning for Suicide (TEC-S) in reducing suicidal thoughts and behaviors (STB) among adults with recent and frequent suicide ideation.
Phase: NA • Sponsor: Massachusetts General Hospital • Aim: Symptom relief
Last updated Apr 26, 2026 20:03 UTC
-
New cell therapy takes on Drug-Resistant melanoma
Disease control Not yet recruitingThe protocol is a Simon's 2-stage, non-randomized, open label, multi-site, phase 2 trial for patients with advanced metastatic, recurrent and unresectable malignant melanoma that has recurred or relapsed after prior anti-PD-(L)1 therapy.
Phase: PHASE2 • Sponsor: Rapa Therapeutics LLC • Aim: Disease control
Last updated May 03, 2026 08:06 UTC
-
Engineered immune cells take aim at tough T-Cell cancers
Disease control Not yet recruitingTo determine the safety and efficacy (1-year PFS) of iC9/CD5CAR/IL-15 NK cells as consolidation in patients with aggressive T-cell malignances in first remission.
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated May 03, 2026 08:08 UTC
-
New combo therapy aims to shrink Hard-to-Treat head and neck tumors
Disease control Not yet recruitingThe goal of this clinical trial is to learn if the combination of cemiplimab and fianlimab can improve outcomes compared to cemiplimab alone in adults with Human Papillomavirus Positive HPV-positive head and neck cancer.
Phase: PHASE2 • Sponsor: University of Chicago • Aim: Disease control
Last updated Apr 24, 2026 16:18 UTC
-
Triple threat: radiation plus two drugs targets Hard-to-Treat kidney cancer
Disease control Not yet recruitingTo investigate the objective response rate (ORR) of stereotactic body radiotherapy (SBRT) combined with anlotinib and beromuzumab in locally advanced/metastatic renal cell carcinoma.
Phase: PHASE2 • Sponsor: Fujian Cancer Hospital • Aim: Disease control
Last updated May 01, 2026 16:01 UTC
-
Blood filter device aims to suck cancer cells out of patients with advanced tumors
Disease control Not yet recruitingThis study is a Prospective Single Arm, dual cohort Open Label Feasibility trial to evaluate the initial safety and signal of efficacy of a novel extracorporeal blood purification (EBP) procedure in either mPDAC or mCRC refractory to systemic therapy. Site selection will be depen…
Phase: NA • Sponsor: ExThera Medical Corporation • Aim: Disease control
Last updated May 03, 2026 08:07 UTC
-
New hope for head and neck cancer patients who Can't take standard chemo
Disease control Not yet recruitingThis phase III trial compares cetuxumab to chemotherapy, carboplatin and paclitaxel, with intensity modulated radiation therapy for the treatment of patients with head and neck cancer who are unable to receive cisplatin. Cetuximab is in a class of medications called monoclonal an…
Phase: PHASE3 • Sponsor: NRG Oncology • Aim: Disease control
Last updated Apr 24, 2026 16:06 UTC
-
Shingles vaccine may boost brain cancer therapy in new trial
Disease control Not yet recruitingIn modern practice a trimodality treatment has emerged as standard of care for histologically confirmed glioblastoma. We hypothesize that the additional vaccination against herpes zoster, after surgical resection followed by irradiation therapy and chemotherapy of patients with …
Phase: PHASE4 • Sponsor: University Hospital, Essen • Aim: Disease control
Last updated May 03, 2026 08:05 UTC
-
AI could revolutionize newborn screening for rare metabolic diseases
Diagnosis Not yet recruitingThe goal of this clinical trial is to evaluate whether an artificial intelligence (AI)-based interpretation system can accurately diagnose inherited metabolic disorders in newborns undergoing routine screening. The main questions it aims to answer are: What is the sensitivity an…
Phase: NA • Sponsor: The Children's Hospital of Zhejiang University School of Medicine • Aim: Diagnosis
Last updated May 01, 2026 16:01 UTC